Inhibition of N-2-fluorenyldiacetamide induced hepatic carcinogenesis in rats by chloramphenicol: a dose-related phenomenon with reduced protein binding of carcinogen.
D000081:Acetamides / Q000037:antagonists & inhibitors / Q000494:pharmacology; D000085:Acetates / Q000037:antagonists & inhibitors*; D000577:Amides / Q000037:antagonists & inhibitors*; D000818:Animals; D001835:Body Weight; D002273:Carcinogens / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D002701:Chloramphenicol / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004032:Diet; D008099:Liver / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced; D008113:Liver Neoplasms / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008954:Models, Biological; D009362:Neoplasm Metastasis; D009374:Neoplasms, Experimental / Q000139:chemically induced; D011485:Protein Binding / Q000187:drug effects*; D014176:Protein Biosynthesis; D051381:Rats; D013997:Time Factors
D000081:Acetamides; D000085:Acetates; D000577:Amides; D002273:Carcinogens; D002701:Chloramphenicol